Cardiac muscle diseases in genetically engineered mice: evolution of molecular physiology.
Recent advances in molecular, cellular, and genetically based technologies now offer the possibility of generating genetically engineered mice that display physiological phenotypes with direct relevance to human pathophysiological states. The ability to create gene ablations, gene duplications, and gene modifications should allow the use of genetic approaches to map in vivo pathways responsible for complex physiological phenotypes. Recent work from our laboratory utilizing this approach to study cardiac muscle diseases in both the adult context (cardiac hypertrophy) and in the embryonic context (congenital ventricular defects) will be discussed, as well as the steps that led to the generation and characterization of these novel mouse model systems. A large body of work from independent laboratories now points to the inception of a new field of molecular physiology that will fuse mouse genetics and in vivo physiology using appropriate miniaturized physiological technology. Recent advances and prospects for future directions are summarized.
Chien
K R
KR
Department of Medicine, University of California San Diego, La Jolla 92093-0613, USA.
D000818:Animals; D006332:Cardiomegaly / Q000503:physiopathology; D009202:Cardiomyopathies / Q000235:genetics*; D005314:Embryonic and Fetal Development; D005818:Genetic Engineering; D006321:Heart / Q000196:embryology / Q000254:growth & development; D006330:Heart Defects, Congenital / Q000235:genetics; D051379:Mice; D008822:Mice, Transgenic; D008967:Molecular Biology / Q000639:trends